Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
38
MIST Quote, Financials, Valuation and Earnings
Last price:
$2.08
Seasonality move
:
-12.37%
Day range:
$1.90 - $2.10
52-week range:
$0.63 - $3.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.10x
Volume:
6.4M
Avg. volume:
8.1M
1-year change:
11.89%
Market cap:
$166.1M
Revenue:
--
EPS (TTM):
-$0.86
Analysts' Opinion
-
Consensus RatingMilestone Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.60, Milestone Pharmaceuticals, Inc. has an estimated upside of 238.46% from its current price of $2.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $2.07.
Fair Value
-
According to the consensus of 4 analysts, Milestone Pharmaceuticals, Inc. has 238.46% upside to fair value with a price target of $6.60 per share.
MIST vs. S&P 500
-
Over the past 5 trading days, Milestone Pharmaceuticals, Inc. has underperformed the S&P 500 by -13.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Milestone Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Milestone Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Milestone Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Milestone Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Milestone Pharmaceuticals, Inc. reported earnings per share of -$0.12.
Enterprise value:
140.7M
EV / Invested capital:
1.81x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.04x
EV / Free cash flow:
-3.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$647K
Return On Assets:
-81.65%
Net Income Margin (TTM):
--
Return On Equity:
-858.37%
Return On Invested Capital:
-93.03%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.5M | -- | -- | -- | -- | |
| Gross Profit | $4M | -$611K | -$647K | -$25K | -$25K | |
| Operating Income | -$61.4M | -$43.8M | -$57.5M | -$9.7M | -$11.9M | |
| EBITDA | -$61M | -$43.2M | -$56.9M | -$9.7M | -$11.9M | |
| Diluted EPS | -$1.38 | -$0.90 | -$0.86 | -$0.14 | -$0.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $132.8M | $82.9M | $84.8M | $81M | $86.7M | |
| Total Assets | $133.8M | $85.8M | $87.1M | $82.7M | $87.8M | |
| Current Liabilities | $5.8M | $6.5M | $8.1M | $5.3M | $10.5M | |
| Total Liabilities | $6.4M | $8.6M | $58.6M | $58.7M | $67.2M | |
| Total Equity | $127.4M | $77.2M | $28.5M | $24M | $20.5M | |
| Total Debt | $766K | $2.1M | $50.5M | $53.4M | $56.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.2M | -$31.1M | -$43.2M | -$7M | -$9.8M | |
| Cash From Investing | -$24.3M | $2.7M | $27.8M | $6.4M | -$35.6M | |
| Cash From Financing | $48.1M | $31.3M | $49.3M | $175.6K | $49.7M | |
| Free Cash Flow | -$48.4M | -$31.2M | -$43.2M | -$7M | -$9.8M | |
MIST
Sector
Market Cap
$166.1M
$28.1M
Price % of 52-Week High
63.73%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
-29.43%
-1.49%
1-Year Price Total Return
5.41%
-17.13%
Beta (5-Year)
0.408
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.13
200-day SMA
Buy
Level
$1.76
Bollinger Bands (100)
Buy
Level
1.7 - 2.32
Chaikin Money Flow
Sell
Level
-12.7M
20-day SMA
Sell
Level
$2.45
Relative Strength Index (RSI14)
Sell
Level
41.60
ADX Line
Sell
Level
35.47
Williams %R
Neutral
Level
-76.5517
50-day SMA
Sell
Level
$2.18
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Sell
Level
-117.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.4096)
Sell
CA Score
(Annual)
Level (-4.3842)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.1979)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Stock Forecast FAQ
In the current month, MIST has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MIST average analyst price target in the past 3 months is $6.60.
-
Where Will Milestone Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Milestone Pharmaceuticals, Inc. share price will rise to $6.60 per share over the next 12 months.
-
What Do Analysts Say About Milestone Pharmaceuticals, Inc.?
Analysts are divided on their view about Milestone Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Milestone Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Milestone Pharmaceuticals, Inc.'s Price Target?
The price target for Milestone Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $6.60 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MIST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Milestone Pharmaceuticals, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MIST?
You can purchase shares of Milestone Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Milestone Pharmaceuticals, Inc. shares.
-
What Is The Milestone Pharmaceuticals, Inc. Share Price Today?
Milestone Pharmaceuticals, Inc. was last trading at $2.08 per share. This represents the most recent stock quote for Milestone Pharmaceuticals, Inc.. Yesterday, Milestone Pharmaceuticals, Inc. closed at $2.07 per share.
-
How To Buy Milestone Pharmaceuticals, Inc. Stock Online?
In order to purchase Milestone Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MIST Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MIST
Sector
P/E ratio
--
23.89x
PEG ratio
-0.04x
-0.01x
P/B ratio
8.10x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
MIST
Sector
Revenue growth
--
4.62%
Earnings growth
13.39%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.17
-$0.21
Profitability
MIST
Sector
Profitability FY 2024
-$646K
$3.6M
Return on invested capital
-93.03%
-31.84%
Return on assets
-81.65%
-27.96%
Return on equity
-858.37%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
12
Estimated Next Earnings Date
Feb
11
Balance Sheet
MIST
Sector
Total cash
$82.6M
$26.4M
Short term investments
$44.4M
$25.7M
Total assets
$75.5M
$76.9M
Long term debt
$56.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
